A Clinical Trial of Insulin Therapy for Dexamethasone Induced Hyperglycaemia amongst Diabetes Patients with COVID-19

Phase 4

• Conditions: COVID-19; Type 2 diabetes; Steroid induced hyperglycaemia; Metabolic and Endocrine - Diabetes; Infection - Other infectious diseases; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12621001340820
• Lead Sponsor: Prof NW Cheung

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-06
• Study Completion: 2022-10-24
• Last Update Posted: 5 August 2024

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1) have a confirmed diagnosis of COVID-19
2) are in a non-ICU ward, and are not imminently to be admitted to ICU or discharged
3) have known diabetes or newly diagnosed diabetes (diagnosed on an HbA1c >=6.5 mmol/L)
4) have had at least one fingerprick glucose level >=12 mmol/L since the commencement of dexamethasone.

Exclusion Criteria

1) pregnant
2) type 1 diabetes
3) eGFR <30

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the mean daily glucose level during the course of the trial. This will be calculated from glucose readings taken from before and after meals. Both formal venous and fingerprick glucose measurements will be accepted.[ Daily pre and post meals, from the day of randomisation to the final day that the patient is in the trial.]